CANADIAN DRUG PLAN SPENDING ON SPECIALTY DRUGS, INCLUDING BIOLOGICS, CONTINUES TO INCREASE1,2

Biologic drugs are one of the fastest-growing market segments in the Canadian pharmaceutical industry3

BIOLOGIC DRUGS4

  • Come from living organisms or from their cells

  • Treat common diseases and medical conditions including anemia, diabetes, inflammatory bowel disease, psoriasis, rheumatoid arthritis, hormone deficiencies and some forms of cancer

  • Biologic drugs are generally more complex than chemically produced pharmaceutical drugs

BIOSIMILAR DRUGS4

  • Demonstrate high similarity to a brand name biologic that is already authorized for sale

  • Are authorized based on a comparison to a brand name biologic and enter the market after the expiry of patents and data protection of their brand name biologic

  • Are shown to be similar to their reference biologic but not identical due to the large size, complexity and natural variability of biologic drugs

img9

SPECIALTY DRUGS*, including brand name biologics and biosimilars, ACCOUNTED FOR 27% OF DRUG COSTS on private plans in 20172

*Defined as drugs costing >$10,000 per year.